New anticoagulants for the treatment of venous thromboembolism
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Jornal Brasileiro de Pneumologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000200146 |
Resumo: | Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context. |
id |
SBPT-1_3496db8ee6a4c8c7278f28345ba531d7 |
---|---|
oai_identifier_str |
oai:scielo:S1806-37132016000200146 |
network_acronym_str |
SBPT-1 |
network_name_str |
Jornal Brasileiro de Pneumologia (Online) |
repository_id_str |
|
spelling |
New anticoagulants for the treatment of venous thromboembolismBlood coagulationVenous thromboembolism\therapyVenous thromboembolism\prevention and controlWorldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context.Sociedade Brasileira de Pneumologia e Tisiologia2016-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000200146Jornal Brasileiro de Pneumologia v.42 n.2 2016reponame:Jornal Brasileiro de Pneumologia (Online)instname:Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)instacron:SBPT10.1590/S1806-37562016042020068info:eu-repo/semantics/openAccessFernandes,Caio Julio Cesar dos SantosAlves Júnior,José LeonidasGavilanes,FranciscaPrada,Luis FelipeMorinaga,Luciana KatoSouza,Rogerioeng2016-05-05T00:00:00Zoai:scielo:S1806-37132016000200146Revistahttp://www.jornaldepneumologia.com.br/default.aspONGhttps://old.scielo.br/oai/scielo-oai.php||jbp@jbp.org.br|| jpneumo@jornaldepneumologia.com.br1806-37561806-3713opendoar:2016-05-05T00:00Jornal Brasileiro de Pneumologia (Online) - Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)false |
dc.title.none.fl_str_mv |
New anticoagulants for the treatment of venous thromboembolism |
title |
New anticoagulants for the treatment of venous thromboembolism |
spellingShingle |
New anticoagulants for the treatment of venous thromboembolism Fernandes,Caio Julio Cesar dos Santos Blood coagulation Venous thromboembolism\therapy Venous thromboembolism\prevention and control |
title_short |
New anticoagulants for the treatment of venous thromboembolism |
title_full |
New anticoagulants for the treatment of venous thromboembolism |
title_fullStr |
New anticoagulants for the treatment of venous thromboembolism |
title_full_unstemmed |
New anticoagulants for the treatment of venous thromboembolism |
title_sort |
New anticoagulants for the treatment of venous thromboembolism |
author |
Fernandes,Caio Julio Cesar dos Santos |
author_facet |
Fernandes,Caio Julio Cesar dos Santos Alves Júnior,José Leonidas Gavilanes,Francisca Prada,Luis Felipe Morinaga,Luciana Kato Souza,Rogerio |
author_role |
author |
author2 |
Alves Júnior,José Leonidas Gavilanes,Francisca Prada,Luis Felipe Morinaga,Luciana Kato Souza,Rogerio |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Fernandes,Caio Julio Cesar dos Santos Alves Júnior,José Leonidas Gavilanes,Francisca Prada,Luis Felipe Morinaga,Luciana Kato Souza,Rogerio |
dc.subject.por.fl_str_mv |
Blood coagulation Venous thromboembolism\therapy Venous thromboembolism\prevention and control |
topic |
Blood coagulation Venous thromboembolism\therapy Venous thromboembolism\prevention and control |
description |
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000200146 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000200146 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1806-37562016042020068 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Pneumologia e Tisiologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Pneumologia e Tisiologia |
dc.source.none.fl_str_mv |
Jornal Brasileiro de Pneumologia v.42 n.2 2016 reponame:Jornal Brasileiro de Pneumologia (Online) instname:Sociedade Brasileira de Pneumologia e Tisiologia (SBPT) instacron:SBPT |
instname_str |
Sociedade Brasileira de Pneumologia e Tisiologia (SBPT) |
instacron_str |
SBPT |
institution |
SBPT |
reponame_str |
Jornal Brasileiro de Pneumologia (Online) |
collection |
Jornal Brasileiro de Pneumologia (Online) |
repository.name.fl_str_mv |
Jornal Brasileiro de Pneumologia (Online) - Sociedade Brasileira de Pneumologia e Tisiologia (SBPT) |
repository.mail.fl_str_mv |
||jbp@jbp.org.br|| jpneumo@jornaldepneumologia.com.br |
_version_ |
1750318346414325760 |